Company news
Galectin Therapeutics Inc. news in 2022
Galectin Therapeutics Inc.'s news releases, calls and decks from 2022, newest first.
Galectin Therapeutics to Webcast Corporate Update on December 1, 2022 after Annual Meeting of Stockholders
November 28, 2022
Galectin Therapeutics to Present at 6th Obesity & NASH Drug Development Summit
November 27, 2022
Galectin Therapeutics Reports Financial Results for the Quarter Ended September 30, 2022 and Provides Business Update
November 13, 2022
Galectin Therapeutics to Share Five Scientific Presentations at The Liver Meeting™ 2022, Hosted by the AASLD
October 31, 2022
Galectin Therapeutics to Present in Upcoming Conferences
October 13, 2022
Galectin Therapeutics Receives FDA Approval to Proceed with Combination Immunotherapy Trial in Head and Neck Cancer
October 11, 2022
Galectin Therapeutics Reports the Positive Outcome of the Second Data and Safety Monitoring Board Meeting for NAVIGATE, its Seamless, Adaptive Phase 2b/3 Study of Belapectin in Patients with Liver Cirrhosis Caused by Non-Alcoholic Steatohepatitis
October 5, 2022
Galectin Therapeutics to Participate in the H.C. Wainwright 24th Annual Global Investment Conference September 13, 2022
September 7, 2022
Galectin Therapeutics Reports Financial Results for the Quarter Ended June 30, 2022 and Provides Business Update
August 14, 2022
Galectin Therapeutics Announces $60 Million Credit Line from Richard E. Uihlein Sufficient to Cover Expected Expenditures Through 2024
July 25, 2022
Galectin Therapeutics Announces 2 Liver Cirrhosis Scientific Presentations at the EASL International Liver Congress™ 2022
June 20, 2022
Galectin Therapeutics to Present in Upcoming H.C. Wainwright Global Investment Conference and the 5th Global NASH Congress
May 22, 2022
Galectin Therapeutics Reports Financial Results for the Quarter Ended March 31, 2022 and Provides Business Update
May 15, 2022
Galectin Therapeutics Reports the Positive Outcome of the First Data and Safety Monitoring Board for NAVIGATE, its Seamless, Adaptive Phase 2b/3 Study of Belapectin in Patients with Liver Cirrhosis Caused by Non-Alcoholic Steatohepatitis
April 13, 2022
Galectin Therapeutics Reports 2021 Financial Results and Provides Business Update
March 30, 2022
Galectin Therapeutics to Present at the H.C. Wainwright BioConnect Conference
January 5, 2022